Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Mallinckrodt public limited company (MNK)
NYSE MKT:MNK
reports
Mallinckrodt public limited company (MNK) Stock Price & Analysis
4 Followers
MNK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.10 - $31.00
Previous Close$1.31
Volume249.65K
Average Volume (3M)1.48M
Market Cap
$1.70M
Enterprise Value$2.61B
Total Cash (Recent Filing)$480.00M
Total Debt (Recent Filing)$3.09B
Price to Earnings (P/E)>-0.1
Beta0.11
Next Earnings
Aug 08, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-78.90
Shares Outstanding13,170,932
10 Day Avg. Volume298,906
30 Day Avg. Volume1,481,156
Standard Deviation0.24
R-Squared0.00262
Alpha-0.18
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)0.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit53.54
Enterprise Value/Ebitda-3.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Mallinckrodt public limited company News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNK FAQ
What was Mallinckrodt public limited company’s price range in the past 12 months?
Mallinckrodt public limited company lowest stock price was $0.10 and its highest was $31.00 in the past 12 months.
What is Mallinckrodt public limited company’s market cap?
Currently, no data Available
When is Mallinckrodt public limited company’s upcoming earnings report date?
Mallinckrodt public limited company’s upcoming earnings report date is Aug 08, 2023 which is in 59 days.
How were Mallinckrodt public limited company’s earnings last quarter?
Mallinckrodt public limited company released its earnings results on May 09, 2023. The company reported -$18.886 earnings per share for the quarter, missing the consensus estimate of N/A by -$18.886.
Is Mallinckrodt public limited company overvalued?
According to Wall Street analysts Mallinckrodt public limited company’s price is currently Overvalued.
Does Mallinckrodt public limited company pay dividends?
Mallinckrodt public limited company does not currently pay dividends.
What is Mallinckrodt public limited company’s EPS estimate?
Mallinckrodt public limited company’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mallinckrodt public limited company have?
Mallinckrodt public limited company has 13,170,932 shares outstanding.
What happened to Mallinckrodt public limited company’s price movement after its last earnings report?
Mallinckrodt public limited company reported an EPS of -$18.886 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -26.19%.
Which hedge fund is a major shareholder of Mallinckrodt public limited company?
Among the largest hedge funds holding Mallinckrodt public limited company’s share is Cyrus Capital Partners, L.P.. It holds Mallinckrodt public limited company’s shares valued at N/A.
---
Mallinckrodt public limited company Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 48.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $339.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Negative
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-133.56%
Trailing 12-Months
Asset Growth
-33.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mallinckrodt public limited company
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which includes innovative specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of revenue from the United States.
---
Top 5 ETFs holding MNK
Schwab U.S. Broad Market ETF
$19.52K
Up to five ETFs with an Outperform Smart Score that hold MNK. The ETFs are listed according to market value of MNK within the ETF
---
---